MRNA · News · 20260810N
Regulatory Approval Milestones
Moderna, Inc. · 2026-08-10 · Importance 71 · Surprise 60 · In source text
The U.S. Food and Drug Administration approved Moderna’s mRNA-based seasonal influenza vaccine, mFLUSIVA, during the week ended August 15, 2026. Third-party reporting described the approval as a late-stage commercial milestone, while noting that the vaccine will face competition and uncertain post-COVID mRNA adoption. One analyst characterized approximately $1 billion in peak sales as a best-case scenario rather than a confirmed company forecast.
Key facts
- Moderna received FDA approval for its mRNA-based seasonal influenza vaccine. source
- The Seeking Alpha item refers to FDA approval of mFLUSIVA. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Moderna received FDA approval for its mRNA-based seasonal influenza vaccine. |